|
|
|
|
|
|
|
|
"...In the study, the authors assumed, for the sake of analysis, that the "outcomes are likely no worse when chemoresponse testing is performed than when an empiric choice of regimen is made."
However, if, in currently ongoing studies, the assay helps clinicians choose more effective therapies and thus improve survival, it would be "very attractive from a health economics perspective," say the authors, because the current study has already shown it to be cost effective."
The study was funded by Precision Therapeutics.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.